Silverleafe Capital Partners LLC Has $142,000 Holdings in Clover Health Investments, Corp. (NASDAQ:CLOV)

Silverleafe Capital Partners LLC boosted its stake in Clover Health Investments, Corp. (NASDAQ:CLOV) by 182.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 45,000 shares of the company’s stock after purchasing an additional 29,091 shares during the period. Silverleafe Capital Partners LLC’s holdings in Clover Health Investments were worth $142,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the stock. Geode Capital Management LLC lifted its stake in shares of Clover Health Investments by 21.9% in the third quarter. Geode Capital Management LLC now owns 4,828,701 shares of the company’s stock worth $13,622,000 after acquiring an additional 868,501 shares during the period. State Street Corp raised its stake in Clover Health Investments by 65.0% during the third quarter. State Street Corp now owns 2,189,380 shares of the company’s stock worth $6,174,000 after buying an additional 862,621 shares during the last quarter. XTX Topco Ltd bought a new stake in Clover Health Investments during the second quarter valued at $932,000. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Clover Health Investments by 75.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,128,171 shares of the company’s stock worth $3,181,000 after acquiring an additional 485,987 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Clover Health Investments in the 3rd quarter worth about $1,228,000. 19.77% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

CLOV has been the topic of several research analyst reports. UBS Group initiated coverage on Clover Health Investments in a research report on Monday, October 7th. They set a “neutral” rating and a $4.00 target price on the stock. Craig Hallum began coverage on Clover Health Investments in a research note on Tuesday, December 17th. They issued a “buy” rating and a $6.00 price target on the stock.

Clover Health Investments Stock Performance

Shares of NASDAQ CLOV traded up $0.11 during trading on Monday, hitting $3.40. 2,336,831 shares of the company traded hands, compared to its average volume of 3,796,601. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of -17.00 and a beta of 1.95. The business’s fifty day moving average is $3.42 and its 200 day moving average is $2.84. Clover Health Investments, Corp. has a fifty-two week low of $0.61 and a fifty-two week high of $4.71.

Clover Health Investments (NASDAQ:CLOV) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.01. The business had revenue of $330.99 million for the quarter, compared to analyst estimates of $347.60 million. Clover Health Investments had a negative return on equity of 25.46% and a negative net margin of 5.92%. During the same quarter in the prior year, the company earned ($0.09) earnings per share. On average, analysts predict that Clover Health Investments, Corp. will post -0.12 EPS for the current year.

Clover Health Investments Company Profile

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.